Recently, Lauweryset al. 94 examined the safety, immunogenicity, and biologic effects of active immunization with IFN-α kinoid in 28 patients with mild to moderate SLE in a randomized, double-blind, placebo-controlled, phase I/II dose-escalation study. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.